Pharmacokinetics of enfuvirtide in a patient with impaired renal function

Clifford Leen, Cynthia Wat, Keith Nieforth

Research output: Contribution to journalArticlepeer-review

Abstract

Enfuvirtide is the first member of the fourth class of antiretroviral drugs to become available. We present a case report of a human immunodeficiency virus (HIV)-positive patient with mild renal impairment who developed severe renal impairment secondary to tenofovir therapy while receiving enfuvirtide. Because the patient's pharmacokinetic profile was not significantly altered, compared with that of HIV-infected patients with normal renal function, no dose modifications were required.
Original languageEnglish
Pages (from-to)e119-21
JournalClinical Infectious Diseases
Volume39
Issue number11
DOIs
Publication statusPublished - 1 Dec 2004

Keywords

  • Adult
  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • HIV Seropositivity
  • Humans
  • Kidney Diseases
  • Male
  • Peptide Fragments

Fingerprint

Dive into the research topics of 'Pharmacokinetics of enfuvirtide in a patient with impaired renal function'. Together they form a unique fingerprint.

Cite this